HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3,4- dipropyl- 4,5,7,8- tetrahydro- 3H- imidazo(1,2- i)purin- 5- one

structure in first source

Also Known As:

3,4-DP-TIP; 3,4-dipropyl-4,5,7,8-tetrahydro-3H-imidazo(1,2-i)-purin-5-one; XT-611

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - 3,4-dipropyl-4,5,7,8-tetrahydro-3H-imidazo(1,2-i)purin-5-one: 1

Experts

1.	Baba, Kenji: 1 article (02/2002)
2.	Hasegawa, Takaaki: 1 article (02/2002)
3.	Kitaichi, Kiyoyuki: 1 article (02/2002)
4.	Miyamoto, Ken-ichi: 1 article (02/2002)
5.	Shibata, Eiji: 1 article (02/2002)
6.	Suzuki, Ryujiro: 1 article (02/2002)
7.	Takagi, Kenji: 1 article (02/2002)
8.	Takagi, Kenzo: 1 article (02/2002)
9.	Takeuchi, Masayuki: 1 article (02/2002)
10.	Tatsumi, Yasuaki: 1 article (02/2002)

Related Diseases

1.	Asthma (Bronchial Asthma) 02/01/2002 - "These findings suggest that selective PDE 4 inhibitors, including XT-611, may effectively reduce the activities of inflammatory cells in the airway of bronchial asthma patients."

Related Drugs and Biologics

1.	Phosphodiesterase 4 Inhibitors